Ziding Feng
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Supplementary Table S4. Competing risks proportional hazards regression for the associations between race/ethnicity and risk of HCC, decompensated cirrhosis, and death in patients with cirrhosis overall and by cirrhosis etiology
Year:
2025
Supplementary Table S2. ICD-9 codes for type 2 diabetes mellitus, alcohol use disorders, hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, human immunodeficiency virus, and low socioeconomic status
Year:
2025
Supplementary Table S5. Association between race/ethnicity and risk of cirrhosis decompensation in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020
Year:
2025
Supplementary Table S6. Association between race/ethnicity and risk of all-cause mortality in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020
Year:
2025
Background: The sensitivity of a cancer screening biomarker to detect prevalent preclinical cancer drives screening benefit. Studies estimate sensitivity at different points in the biomarker development process. We examine how closely these estimates reflect the sensitivity to detect preclinical cancer (preclinical sensitivity). Methods: We posit that preclinical sensitivity is inversely proportional to the preclinical sojourn time. We simulate studies and estimates of sensitivity corresponding to the Early Detection Research Network’s Phases of Biomarker Development. Sensitivity estimates based on clinically diagnosed cases (phase II, clinical sensitivity), archived-sample studies (phase III, archived-sample sensitivity), and prospectively screened cohorts (phases IV and V, prospective empirical sensitivity) are defined and compared against the corresponding expected preclinical sensitivity. Results: Clinical sensitivity is generally optimistic. Archived-sample sensitivity is optimistic near clinical diagnosis but may be pessimistic at longer look-back intervals, with bias also dependent on test specificity. Prospective empirical sensitivity is optimistic when the sojourn time is long relative to the screening interval. Bias in prospective empirical sensitivity also depends on the frequency and accuracy of confirmation testing following a positive screening test. Conclusions: Sensitivity estimates from different phases of biomarker development should be distinguished and labeled accordingly to facilitate a realistic assessment of diagnostic performance and prediction of potential benefit. Impact: Our study highlights the need for clearer terminology to describe the sensitivity of cancer early detection biomarkers. We introduce new labels, explain biases in sensitivity estimates, and advocate for improved communication to enhance understanding of diagnostic test performance.
Year:
2025
Background: Among patients with cirrhosis, it remains unclear whether there are racial/ethnic differences in cirrhosis complications and mortality. We examined the associations between race/ethnicity and risk for hepatocellular carcinoma (HCC), cirrhosis decompensation, and all-cause mortality overall and by cirrhosis etiology. Methods: US Veterans diagnosed with cirrhosis from 2001 to 2014 ( n = 120,992), due to hepatitis C virus (HCV; n = 55,814), alcohol-associated liver disease (ALD; n = 36,323), hepatitis B virus (HBV; n = 1,972), nonalcoholic fatty liver disease (NAFLD; n = 17,789), or other ( n = 9,094), were followed through 2020 for incident HCC ( n = 10,242), cirrhosis decompensation ( n = 27,887), and mortality ( n = 81,441). Multivariable Cox proportional hazards regression was used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Results: Compared with non-Hispanic White patients, Hispanic patients had higher risk for HCC overall (aHR, 1.32; 95% CI, 1.24–1.41) and by cirrhosis etiology, particularly for ALD- (aHR, 1.63; 95% CI, 1.42–1.87) and NAFLD-cirrhosis (aHR, 1.76; 95% CI, 1.41–2.20), whereas non-Hispanic Black patients had lower HCC risk in ALD- (aHR, 0.79; 95% CI, 0.63–0.98) and NAFLD-cirrhosis (aHR, 0.54; 95% CI, 0.33–0.89). Asian patients had higher HCC risk (aHR, 1.70; 95% CI, 1.29–2.23), driven by HCV- and HBV-cirrhosis. Non-Hispanic Black patients had lower risk for cirrhosis decompensation overall (aHR, 0.71; 95% CI, 0.68–0.74) and by cirrhosis etiology. There was lower risk for mortality among all other racial/ethnic groups compared with non-Hispanic White patients. Conclusions: Race/ethnicity is an important predictor for risk of developing HCC, decompensation, and mortality. Impact: Future research should examine factors underlying these racial/ethnic differences to inform prevention, screening, and treatment for patients with cirrhosis.
Year:
2025
Supplementary Table S6. Association between race/ethnicity and risk of all-cause mortality in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020
Year:
2024
Supplementary Table S5. Association between race/ethnicity and risk of cirrhosis decompensation in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020
Year:
2024
Supplementary Table S4. Competing risks proportional hazards regression for the associations between race/ethnicity and risk of HCC, decompensated cirrhosis, and death in patients with cirrhosis overall and by cirrhosis etiology
Year:
2024
Supplementary Table S5. Association between race/ethnicity and risk of cirrhosis decompensation in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (6)
Trang VoPham
Associate Professor
University of Washington
George N. Ioannou
University of Washington
Yingye Zheng
Fred Hutchinson Cancer Research Center
Nicole Kim
Assistant Professor
University of Washington
Jane Lange
Staff Scientist
Oregon Health & Science University
Jason A. Mendoza
Professor
University of Washington
Make your next move.
Prepare your application
Review drafts before you send them.